MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator-Initiated Studies (IIS), announced additional funding from existing investors, Debiopharm Innovation Fund, Nina Capital, and Young Sohn, a co-founder of Veeva Systems. This investment underscores confidence in MedaSystems' ability to modernize pre-approval access pathways through its AI-driven workflow platform.

MedaSystems 是扩展获取（EA）和研究者发起的研究（IIS）领域的领先 SaaS 平台，宣布获得现有投资者 Debiopharm 创新基金、Nina Capital 和 Veeva Systems 联合创始人 Young Sohn 的额外资金支持。这项投资彰显了对 MedaSystems 通过其人工智能驱动的工作流程平台实现审批前获取途径现代化的信心。

By streamlining Expanded Access and IIS workflows, MedaSystems helps pharmaceutical companies and healthcare providers efficiently manage requests, improve patient access, and capture real-world data (RWD) to support evidence generation and regulatory submissions..

通过简化扩展访问和IIS工作流程，MedaSystems帮助制药公司和医疗保健提供者高效管理请求、改善患者获取途径，并收集真实世界数据（RWD）以支持证据生成和监管提交。